Form D · Biotechnology
NewLimit, Inc.
South San Francisco, CA · CIK 0001977037
Offering snapshot reported May 15, 2025 · SEC filing
- Reported sold
- $130M Offering amount: $130M
- Investors reported
- 38 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 2, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 15, 2025 | Initial | $129,799,764 | No comparison | 38 | SEC filing |
| Jan 7, 2025 | Amendment | $72,245,500 | $12,249,997vs May 17, 2023 | 21 | SEC filing |
| May 17, 2023 | Initial | $59,995,503 | No comparison | 19 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-546258
Source: Form D, filed May 15, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brian Armstrong | Director |
| Blake Byers | Director |
| Zavain Dar | Director |
| Jacob Kimmel | Director, Executive |
| Michael Polansky | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
901 Gateway Boulevard
South San Francisco, CA, 94080
South San Francisco, CA, 94080